Allison DeAngelis from STAT News - Journalist Profile

	Profile	Recent Articles on Subject
1	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Biotech led by J&J veterans launches with $165 million for cancer, autoimmune therapies - 4 days ago STAT+: Cardiovascular startup raises $260 million led by ex-Moderna execs’ new VC fund - 10 days ago Listen: Biotech layoffs, founder-focused VC, & a big pharma exit - 15 days ago STAT+: Ahead of ASCO, J&J reports mixed data on next-generation radiopharmaceutical - 2 months ago Listen: More tumult at BIO & coercive care for sickle cell patients - 2 months ago Listen: Controversial brain tissue research, obesity drug sales, and Novartis’ M&A drama - 3 months ago Listen: Vertex’s big deal, biotech’s red numbers, & an industry history lesson - 4 months ago STAT+: Biotech startups post strongest financing numbers in two years - 4 months ago Listen: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise - 4 months ago STAT+: Investors funnel $275 million into Paragon Therapeutics spinout - 4 months ago STAT+: As AI proliferates, biopharma companies seek to harness it in clinical trials - 4 months ago Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech - 4 months ago STAT+: How biotech investors spot opportunity when stocks are down — and up - 4 months ago Listen: Live! From the STAT Breakthrough Summit East - 4 months ago STAT+: Immuno-oncology startup launches with $150 million, ex-Surface, Bluebird exec as CEO - 4 months ago STAT+: Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline - 4 months ago Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard - 4 months ago Listen: VC turmoil, GLP-1 competition, & the war on recovery - 5 months ago STAT+: Biotech FogPharma raises $145 million in anticipation of more clinical trials, pharma partnerships - 5 months ago Listen: Legal insider trading, booming biotech stocks, & the next GLP-1 - 5 months ago STAT+: Biotech launches with $82 million for Parkinson’s cell therapy - 5 months ago Q&A: A biotech VC leader shares her next big bets - 5 months ago Humira’s legacy, CEO symbolism, and genomic surgery - 5 months ago STAT+: Flagship Pioneering startup lays off a third of staff - 5 months ago Listen: Pharma goes to Washington, Alnylam’s future, & Gilead’s dealmaking - 5 months ago STAT+: Biotech launches with $135 million for Vertex-competing pain medicine - 5 months ago STAT+: Startup BioAge raises $170 million Series D for Zepbound combination therapy - 5 months ago Listen: AI in medicine, detangling hype, and Icelandic DNA - 6 months ago STAT+: Eli Lilly reports tirzepatide MASH success during Q4 earnings - 6 months ago Listen: The plight of the VC, Gilead’s latest setback, & more M&A - 6 months ago Biotech layoffs, slumping stocks, and a 2024 preview - 6 months ago STAT Virtual Event \| 2024 JPM Recap, Live! - 7 months ago The highs — and lows — of JPM 2024 you should pay attention to - 7 months ago Listen: Live! From JPM 2024 - 7 months ago STAT+: A biotech reporter’s notebook: Sunshine rains down on San Francisco - 7 months ago STAT+: JPM 2024: FogPharma’s new CEO, Mathai Mammen, unveils ‘contrarian’ plan in oncology - 7 months ago This is the TLDR of JPM Day 1 - 7 months ago STAT+: Feng Zhang, Grail founder join forces on new gene editing startup, Moonwalk - 7 months ago STAT+: Novo Nordisk enlists two Flagship biotechs to develop obesity, MASH drugs - 7 months ago STAT+: Burning questions for the 2024 JPM Healthcare Conference - 7 months ago STAT+: Goldman Sachs launches $650 million fund for life sciences investments - 7 months ago Listen: 2023 in review, CEO report cards, and a look at the year ahead - 7 months ago STAT+: Prime Medicine, Mukherjee’s Myeloid Therapeutics clash over genome-editing deal - 7 months ago Listen: FTC v. biotech, Pfizer’s kitchen sink, & Vertex’s future - 8 months ago STAT+: With big ambition — and a family name to match — Reed Jobs charts his own course in biotech - 8 months ago STAT+: A Q&A with Vertex founder Joshua Boger on Casgevy, the biotech industry, and Elon Musk - 8 months ago Listen: CRISPR history, biotech struggles, & a big week for deals - 8 months ago STAT+: RNA startup ReNAgade cuts staff seven months after raising $300 million - 8 months ago AbbVie’s big deal, CAR-T’s risks, & getting a biotech job - 8 months ago STAT+: Saudi VC loops Novo Nordisk, other biotech VCs into new longevity incubator - 8 months ago
2	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	Listen: Biotech layoffs, founder-focused VC, & a big pharma exit - 15 days ago Listen: More tumult at BIO & coercive care for sickle cell patients - 2 months ago Listen: Controversial brain tissue research, obesity drug sales, and Novartis’ M&A drama - 3 months ago Listen: Vertex’s big deal, biotech’s red numbers, & an industry history lesson - 4 months ago Listen: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise - 4 months ago Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech - 4 months ago Listen: Live! From the STAT Breakthrough Summit East - 4 months ago Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard - 4 months ago Listen: VC turmoil, GLP-1 competition, & the war on recovery - 5 months ago Listen: Legal insider trading, booming biotech stocks, & the next GLP-1 - 5 months ago Humira’s legacy, CEO symbolism, and genomic surgery - 5 months ago Listen: Pharma goes to Washington, Alnylam’s future, & Gilead’s dealmaking - 5 months ago Listen: AI in medicine, detangling hype, and Icelandic DNA - 6 months ago Listen: The plight of the VC, Gilead’s latest setback, & more M&A - 6 months ago Biotech layoffs, slumping stocks, and a 2024 preview - 6 months ago The highs — and lows — of JPM 2024 you should pay attention to - 7 months ago Listen: Live! From JPM 2024 - 7 months ago This is the TLDR of JPM Day 1 - 7 months ago STAT+: Burning questions for the 2024 JPM Healthcare Conference - 7 months ago Listen: 2023 in review, CEO report cards, and a look at the year ahead - 7 months ago Listen: FTC v. biotech, Pfizer’s kitchen sink, & Vertex’s future - 8 months ago Listen: CRISPR history, biotech struggles, & a big week for deals - 8 months ago AbbVie’s big deal, CAR-T’s risks, & getting a biotech job - 8 months ago
3	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	Listen: Biotech layoffs, founder-focused VC, & a big pharma exit - 15 days ago
4	Damian Garde STAT News Biotech reporter at STAT. Open to messages. biotechnologyjournalism	Listen: Vertex’s big deal, biotech’s red numbers, & an industry history lesson - 4 months ago Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech - 4 months ago Listen: Live! From the STAT Breakthrough Summit East - 4 months ago Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard - 4 months ago Listen: VC turmoil, GLP-1 competition, & the war on recovery - 5 months ago Listen: Legal insider trading, booming biotech stocks, & the next GLP-1 - 5 months ago Humira’s legacy, CEO symbolism, and genomic surgery - 5 months ago Listen: Pharma goes to Washington, Alnylam’s future, & Gilead’s dealmaking - 5 months ago Listen: AI in medicine, detangling hype, and Icelandic DNA - 6 months ago Listen: The plight of the VC, Gilead’s latest setback, & more M&A - 6 months ago Biotech layoffs, slumping stocks, and a 2024 preview - 6 months ago The highs — and lows — of JPM 2024 you should pay attention to - 7 months ago Listen: Live! From JPM 2024 - 7 months ago This is the TLDR of JPM Day 1 - 7 months ago STAT+: Burning questions for the 2024 JPM Healthcare Conference - 7 months ago Listen: 2023 in review, CEO report cards, and a look at the year ahead - 7 months ago Listen: FTC v. biotech, Pfizer’s kitchen sink, & Vertex’s future - 8 months ago Listen: CRISPR history, biotech struggles, & a big week for deals - 8 months ago AbbVie’s big deal, CAR-T’s risks, & getting a biotech job - 8 months ago
5	Mario Aguilar STAT News Reporter at STATnews. Previous engagements noted. Personal views. Brooklyn techhealth care	STAT+: How biotech investors spot opportunity when stocks are down — and up - 4 months ago
6	Matthew Herper STAT News Writes at STAT. Biology's century. Undisclosed biologydatajournalism	The highs — and lows — of JPM 2024 you should pay attention to - 7 months ago This is the TLDR of JPM Day 1 - 7 months ago STAT+: Burning questions for the 2024 JPM Healthcare Conference - 7 months ago
7	Mohana Ravindranath STAT News Health tech reporter at STAT. Oakland, CA + Washington, D.C. Health techreporting	STAT+: Burning questions for the 2024 JPM Healthcare Conference - 7 months ago
8	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	STAT+: Prime Medicine, Mukherjee’s Myeloid Therapeutics clash over genome-editing deal - 7 months ago